OncoMatch/Clinical Trials/NCT06863272
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Is NCT06863272 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for castration-resistant prostatic cancer.
Treatment: Docetaxel · Ifinatamab Deruxtecan · MK-5684 · Abiraterone · Enzalutamide · Rescue Medication — The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen receptor pathway inhibitor
Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
Must have received: poly-ADP-ribose polymerase inhibitor
Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Cannot have received: taxane-based chemotherapy
Exception: for metastatic castration-resistant prostate cancer (mCRPC)
Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Medical Center at Mission Bay ( Site 0034) · San Francisco, California
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026) · Washington D.C., District of Columbia
- UPMC Hillman Cancer Center ( Site 0014) · Pittsburgh, Pennsylvania
- The West Clinic, PLLC dba West Cancer Center ( Site 0005) · Germantown, Tennessee
- Fred Hutchinson Cancer Center ( Site 0013) · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify